lower Hello, you update. you, November, top today potential line we believe is clinically key excited received that patients evaluated mortality severe larsucosterol for for had hepatitis. quarter Thank from patients. Phase trial, The results the that benefit patients We're these treated compared Thank in joining to they fourth with takeaway placebo. for everyone. our show provide larsucosterol IIb and AH these days which us results .
Last results Tim. the larsucosterol our alcohol-associated AHFIRM in with survival XXXX a XX from clinical at about announced meaningful
of improvement mortality this our demonstrated To in controlled has devastating trial no an in disease. previously magnitude this knowledge,
also an We the encouraging placebo. for larsucosterol active a arms profile of safety events compared with saw for adverse lower as with number
design that We in confirmatory basis NDA ongoing about FDA trial potential the as Phase III for communications filing. an the for the could are a serve with
second the update provide quarter. We expect in to a further
the to the patients. community by leaders thought continue have We who support be no these therapy and broader encouraged AH for of effective overwhelming had hepatology
We arm XX infection. antibiotics was of arms AHFIRM XX AH, to the with of as active practice a placebo allow and double-blind, which milligrams multinational in larsucosterol X placebo-controlled, to a XXX allow trial of approximately nutritional Our IIb fluids as use study of corticosteroids milligrams as each. care Phase supportive for for and their utilize well and for treating physicians standard support patients addition such
including network EU leading Australia, clinical the and U.K. severe sites, from with global of AH In the the United total, we randomized in XXX hospitals patients a States,
world's the the in with XX-milligram a XX% preeminent honor when with renowned results showed mortality Our centers, dose AH. included days top in XX compared XX-milligram and of the reduction The we had the XX% of secondary the thought key at of liver working endpoint reduction placebo. leaders larsucosterol some with and sites dose of a line larsucosterol with of
the which a U.S. numerical that in improvement the as reported compared U.S. of reduction XX% or of in a mortality was with impressive neither of saw results though XX transplant of endpoint reductions with XXX patients. comprised AHFIRM, total enrollment in at were XXX liver in mortality also the XX% significance. patients, arms, the and the Even We in more placebo. population, X/X primary and results primary out the secondary respectively, we endpoint XX XX-milligram key days, observed statistical or achieved In
in Although not reductions in were patients. the the both number analysis the larsucosterol approximately with than an these plan, no part adverse results either greater of events excellent importantly, the Very in ill active treatment-emergent arm safety both XX% arms for p-values serious events X.XX. severely profile and for original adverse exhibited statistical of
mortality, events a reductions in clinically for these Ultimately, reinforce in risk in patients larsucosterol. with meaningful proposition ill reward coupled severely reduction these adverse the compelling
communication trial the We AH. confirmatory design in with the a FDA are about active of in Phase III
patients. believe the evidence data effective AHFIRM We provide and that safe that therapy with potential compelling a life-saving represent for to larsucosterol continue could AH
each thousands XX%, reminder, in the and XXX,XXX tens a it's the it a year. AH. year no to U.S. approximately than hospitalizations deaths for mortality this AH There Larsucosterol approval, disease. with the rate of XX-day each cause able expectations for gain responsible of are of FDA-approved we treatment be in III, likely is As are and meets more of for effective would first Phase our treatments
addition to hospitals $XXX,XXX. Hospitalizations cost a costs $XX,XXX from system. AH to cost ranging the rate, attributed In This significant to billion represents typically annually. care mortality health a in $XX over incur of AH total a approximately U.S. results to high to
to have. would As any represents opportunity alone. provide system. United take like to a result, you care multibillion-dollar could potential now simultaneous may savings larsucosterol overall the health States It in a questions cost the We
